Zoono's share price slumps after covid serves mixed results

Zoono's share price slumps after covid serves mixed results
A Transport for London worker sprays anti viral solution Zoono-71 inside a tube train north London in May 2020.
Denise McNabb
Covid-19 is turning out to be a double-edged sword for ASX-listed New Zealand antimicrobials company, Zoono Group. Its hand sanitiser sales had benefited from the virus, but chief executive Paul Hyslop said demand for the company’s surface sanitising spray has been hampered by lockdowns leaving offices empty and delaying the need for disinfection protection.“While the company has overall undoubtedly benefited from the impact of the covid-19 pandemic, in many respects the opposite has been the case in the review period in that t...

More Markets

NZ sharemarket down 1.13% for the week
Markets Market close

NZ sharemarket down 1.13% for the week

The S&P/NZX 50 Index closed at 11,796.21, down 39.83 points or 0.34%.

Graham Skellern 19 Apr 2024
Bell Potter boosts Santana target price 53.5%
Primary Sector

Bell Potter boosts Santana target price 53.5%

Aussie brokers increasingly like the look of a low-cost, high yield Otago gold play.

Pattrick Smellie 19 Apr 2024
Anna Palairet appointed Fonterra's chief operating officer
Primary Sector

Anna Palairet appointed Fonterra's chief operating officer

Having acted in the role since June last year, she replaces Fraser Whineray.

Riley Kennedy 19 Apr 2024
Analysts upbeat about Tower's latest guidance
Markets

Analysts upbeat about Tower's latest guidance

The insurer's shares have gained 36% so far this year. 

Rebecca Howard 19 Apr 2024